Skip to content
buyWeak

David Owens bought $1,095 of NXL

Chief Medical Officer at Nexalin Technology, Inc.. 500 shares at an average of $2.19, traded Oct 28, 2024, filed Oct 30, 2024.

Conviction score
10
Value
$1,095
500 shares
Holdings after
148,293
+0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $1k at market
    0
  • Relative to holdings
    Under 1% of holdings (0.3%)
    -5
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +83.3%, 3m +14.0%, 6m -20.2%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

NXLOct 12, 2026 · close 3.36
Since filing Oct 30, 2024: -95.1%SPY +37.2% · excess -132.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001829126-24-007091, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 28, 2024POpen-market purchase
Common stock
+500$2.19$1,095148,293Oct 30, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

David Owens bought $1,095 of NXL | InsiderTell